Navigation Links
Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
Date:2/16/2011

Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus' candidate drug products and the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical st
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
2. Amicus Therapeutics Opens Research Facility in San Diego
3. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
5. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
10. Amicus Therapeutics Announces Change to Board of Directors
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Altamonte Springs, FL (PRWEB) December 18, 2014 ... one of the nation’s leading specialty pharmacies, has ... who serve as clinical pharmacy consultants for prescriber ... disease therapy expertise. , “We have a ... disease therapies. For example, those specializing in hepatitis ...
(Date:12/19/2014)... CAMBRIDGE, MA (PRWEB) December 18, 2014 ... adults in the United States suffer from one or ... arthritis, asthma, or cancer. Medication can address some of ... to daily activities that many sufferers face. While implanted ... surgery and stimulate the whole nerve, which can induce ...
(Date:12/19/2014)... 2014 With only 2 weeks left ... on Sartorius Biohit products . The product specials include ... Electronic Pipette Trade-in Program, and free pipette tips. , ... around the world. They are ideal for lab technicians ... ,     Full volume range of 0.1 uL ...
(Date:12/19/2014)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced the results of its annual general meeting ... transformational year in Relmada,s history and it set the ... Sergio Traversa , chief executive officer of Relmada. ... financial, human resource and clinical development objectives that position ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... NEW YORK, Oct. 15 Senex Biotechnology, Inc. ... at the 8th International,Conference on Alzheimer,s Disease Drug ... of Senex, described the identification of the first,drug ... amounts of,several proteins involved in Alzheimer,s disease, including: ...
... Cellulosic Ethanol Summit in ... ... Genencor, a division of,Danisco A/S, today announced a new product, ... for,second generation biorefineries. Accellerase(TM) 1000 contains a potent,complex of enzymes ...
... Luminex Corporation,(Nasdaq: LMNX ) today announced that it ... ("RBM"). As part of the settlement, Luminex,received a cash ... by RBM,in exchange for resolution of the dispute between ... of Luminex,s stock,ownership in RBM and the grant of ...
Cached Biology Technology:Senex Biotechnology Announces Presentation of Alzheimer's Disease Drug Discovery Effort 2Senex Biotechnology Announces Presentation of Alzheimer's Disease Drug Discovery Effort 3Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol 2Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol 3
(Date:11/18/2014)... , Nov. 18, 2014  The Secure ... Industry Association today jointly announce the formation of ... release of its Identity and Biometric Entry ... The Framework received official support from BORDERPOL, the ... to improve and provide expertise regarding border security, ...
(Date:11/18/2014)...   EyeLock Inc. , a market leader ... USA (Safran), a leading U.S. provider of ... partnership to offer comprehensive biometric identity solutions and ... screening and financial services markets. As ... through a nationwide network of 1,100 IdentoGO® Centers.  ...
(Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... team led by scientists from the National Oceanography Centre in ... the region of the North Atlantic Ocean affected by ash ... ocean biology. In many regions of the ocean the ... of the marine food web and sequester carbon dioxide from ...
... ,, CARROLLTON, Ga. , April 27 Greenway ... (EHR), practice management and interoperability solution Prime Suite ®, has been ... NYC Regional Electronic Adoption Center for Health ( NYC REACH ). ... NYC ...
... CA: Providing healthier food choices for our nation,s ... Move campaign. And a team of researchers from ... help schools serve more fresh vegetables and salad items. ... and Brand Lab, presented the findings of the study ...
Cached Biology News:Scientists to measure impact of volcanic ash on ocean biology 2New York City Regional Extension Center Selects Greenway 2New York City Regional Extension Center Selects Greenway 3New York City Regional Extension Center Selects Greenway 4
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
... PrecisION Ion Channel Cell Lines ,High Quality, ... channels are well known for having a ... and consequently have a key function in ... modulate ion channels have been investigated in ...
Mouse monoclonal antibody raised against a partial recombinant ENTPD5. NCBI Entrez Gene ID = ENTPD5...
... Protein Staining Solution stains proteins ... electrophoresis (detection limit >= 8 ng ... including washing and destaining processes can ... staining of gel (20 min), proteins ...
Biology Products: